Key result
Direct oral anticoagulants reduced thromboembolic events and bleeding events compared to vitamin K antagonists in cancer patients with AF.
Why the study?
Cancer and AF may be associated, requiring anticoagulation to prevent thromboembolic events while minimizing bleeding, but comparative safety and efficacy between DOACs and VKAs needed evaluation.
Do direct oral anticoagulants reduce thromboembolic and bleeding events compared to vitamin K antagonists in oncological patients with atrial fibrillation?
Meta-Analysis (n=228,497)
Do direct oral anticoagulants reduce thromboembolic and bleeding events compared to vitamin K antagonists in oncological patients with atrial fibrillation?
Answers are grounded in this paper and cite their sources.
In patients with atrial fibrillation and active or remote cancer, DOACs provide superior protection against both thromboembolic events (including ischemic stroke, MI, and VTE) and major bleeding compared to VKAs, with similar efficacy and safety across individual DOAC agents.
Background and aim. Cancer and atrial fibrillation (AF) may be associated, and anticoagulation, either with vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs), is necessary to prevent thromboembolic events by reducing the risk of bleeding. The log incidence rate ratio (IRR) and 95% confidence interval were used as index statistics. Higgin’s I2 test was adopted to assess statistical inconsistencies by considering interstudy variations, defined by values ranging from 0 to 100%. I2 values of less than 40% are associated with very low heterogeneity among the studies; values between 40% and 75% indicate moderate heterogeneity, and those greater than 75% suggest severe heterogeneity. The aim of this meta-analysis was to compare the safety and efficacy of VKAs and DOACs in oncologic patients with AF. Methods. A meta-analysis was conducted comparing VKAs to DOACs in terms of thromboembolic events and bleeding. A meta-regression was conducted to investigate the differences in efficacy and safety between four different DOACs. Moreover, a sub-analysis on active-cancer-only patients was conducted. Results. A total of eight papers were included. The log incidence rate ratio (IRR) for thromboembolic events between the two groups was −0.69 (p < 0.005). The meta-regression did not reveal significant differences between the types of DOACs (p > 0.9). The Log IRR was −0.38 (p = 0.008) for ischemic stroke, −0.43 (p = 0.02) for myocardial infarction, −0.39 (p = 0.45) for arterial embolism, and −1.04 (p = 0.003) for venous thromboembolism. The log IRR for bleeding events was −0.43 (p < 0.005), and the meta-regression revealed no statistical difference (p = 0.7). The log IRR of hemorrhagic stroke, major bleeding, and clinically relevant non-major bleeding between the VKA and DOAC groups was −0.51 (p < 0.0001), −0.45 (p = 0.03), and 0.0045 (p = 0.97), respectively. Similar results were found in active-cancer patients for all the endpoints except for clinically-relevant non-major bleedings. Conclusions. DOACs showed better efficacy and safety outcomes than VKAs. No difference was found between types of DOACs.
No takes yet. Share an insight, caveat, or question.
Parrini et al. (2022) conducted a meta-analysis in Atrial fibrillation with active or remote cancer (n=228,497). Direct oral anticoagulants (apixaban, rivaroxaban, dabigatran, edoxaban) vs. Vitamin K antagonists (predominantly warfarin) was evaluated on Total thromboembolic events (composite of venous thromboembolism, arterial thromboembolism, ischemic stroke, and myocardial infarction) (log IRR -0.6921, 95% CI -1.1097 to -0.2745, p=0.0012). Direct oral anticoagulants reduced thromboembolic events and bleeding events compared to vitamin K antagonists in cancer patients with AF.
Synapse has enriched 10 related papers. Consider them for comparative context: